Pharmaceutical composition for treating apoplexy and preparation method thereof

A composition and drug technology, applied in drug combination, drug delivery, medical formula, etc., can solve the problems of rare types of complex stroke syndromes, inconvenient use, and complicated drug properties, and achieve good curative effect, easy absorption, and anti-inflammatory effects. The effect of rheumatism

Active Publication Date: 2006-12-27
通化卫京药业股份有限公司
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Taking a comprehensive look at these varieties, it is clear that there are not many varieties with a compound syndrome of stroke, and the dosage form of the above-mentioned medicines is mostly pills, which is inconvenient to use
[0006] In recent years, research on the prevention and treatment of similar diseases has been very active, and various therapeutic drugs have appeared on the market. There are also invention patents for such drugs, but most traditional Chinese medicine preparations contain many medicinal materials and complex properties.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The preparation of embodiment 1 oral liquid

[0056] 1. Weigh the crude drug raw materials according to the following quantities: 600g of Herba chinensis, 50g of safflower and 50g of Chuanniu lacquer;

[0057] 2. Add water to decoct each component twice, add water 4000-5000ml each time, 30 minutes each time; combine the decoction liquid, filter and concentrate to obtain 70-85g of extract, and the yield of extract is 10%-12%. The density of the extract at 50°C is 1.10-1.12g / ml 3 ;

[0058] 3. Cool naturally, add 3g of stevioside to it, add 100ml of medicinal rice wine, add purified water to 1000ml, shake well, filter, and divide into 100 vials of 10ml.

[0059] The pH of the obtained oral liquid was about 5.0, and the crude drug content was 7 g of crude drug per 10 ml.

Embodiment 2

[0060] Embodiment 2 preparation of oral liquid

[0061] 1. Weigh the crude drug raw materials according to the following quantities: 600g of Herba chinensis, 50g of safflower and 50g of Chuanniu lacquer;

[0062] 2. Add 5000ml of 75% ethanol to all medicinal materials and extract under reflux for 1 hour, filter, concentrate and recover ethanol to obtain 2-3g of extract, and the yield of extract is 3%-4%.

[0063] 3. Add water to decoct the dregs of the previous step twice, add 4000-5000ml of water each time, 30 minutes each time, combine the decoction liquid, filter and concentrate to obtain a relative density of 1.10-1.12g / ml at 50°C 3 70-85g of the extract, the yield of the extract is 10%-12%,;

[0064] 4. Cool naturally, combine with the extract obtained in step 2, add 3g of stevioside to it, add purified water to 1000ml, shake well, filter, and distribute in 100 vials of 10ml.

[0065] The crude drug content in the obtained oral liquid contained 7 g of crude drugs per 10...

Embodiment 3

[0066] Embodiment 3 The influence of oral liquid of the present invention on thrombus formation in rats

[0067] The in vivo thrombus formation time was measured by an in vivo thrombus formation instrument.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition for treating apoplexy and / or after-effect of apoplexy, its preparing process and pharmaceutical use, wherein the composition comprises active constituents (by weight ratio) of Siegesbeckia orientalis L. 200-1000, safflower 10-100, cyathula root 10-100, and selectively contains one or more medicinal carrying agents.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, specifically, the present invention relates to a pharmaceutical composition for treating apoplexy, as well as the preparation method and application of the composition. paint, and may contain one or more pharmaceutically acceptable carriers. Background technique [0002] Stroke, namely acute cerebrovascular disease, is a common disease that seriously damages human health. It is a frequently-occurring and common disease in adults, especially the elderly, and is one of the three major mortality diseases of human beings. According to the results of our country's epidemiological survey. The number of stroke patients in my country has reached 4-5 million, and the number of new cases each year has reached 1.3 million. Due to its high morbidity, mortality, disability and recurrence, it is extremely harmful to human health. [0003] According to the cause and nature of the onset, stroke is divide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/286A61K9/08A61K9/10A61P9/10
Inventor 杜衛京
Owner 通化卫京药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap